HCmed Innovations CoTPE:6934 -2.16%11 EBITDA Margin % is 16.60% as of Dec. 2025. GuruFocus rates TPE:6934 with a GF Score™ of 11/100. The stock has 4 warning signs investors should review. Among 815 Medical Devices & Instruments companies, HCmed Innovations Co ranks worse than 71.53% on this metric.
HCmed Innovations Co (TPE:6934) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
HCmed Innovations Co EBITDA Margin % Related Terms
HCmed Innovations Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for HCmed Innovations Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6934 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, HCmed Innovations Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCmed Innovations Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HCmed Innovations Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where HCmed Innovations Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCmed Innovations Co (TPE:6934) has a EBITDA Margin % of 16.60% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HCmed Innovations Co and its competitors. According to the industry distribution chart, HCmed Innovations Co ranks #583 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 71.5%.
Is HCmed Innovations Co's EBITDA Margin % too high?
HCmed Innovations Co's current EBITDA Margin % is 16.60%. The Medical Devices & Instruments industry median EBITDA Margin % is 7.47. HCmed Innovations Co's value of 16.60% is 122.2% above this industry median. Based on the distribution chart, HCmed Innovations Co ranks #583 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, HCmed Innovations Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does HCmed Innovations Co's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HCmed Innovations Co ranks #583 out of 815 companies for EBITDA Margin %. This places HCmed Innovations Co in the lower half of its industry. The industry median EBITDA Margin % is 7.47. HCmed Innovations Co's value of 16.60% is 122.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HCmed Innovations Co's current EBITDA Margin % of 16.60% is 122.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HCmed Innovations Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCmed Innovations Co's current EBITDA Margin % is 16.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCmed Innovations Co stock overvalued right now?
HCmed Innovations Co (TPE:6934) has a current EBITDA Margin % of 16.60%. The current EBITDA Margin % is 16.60% and 122.2% above the Medical Devices & Instruments industry median of 7.47. HCmed Innovations Co's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For HCmed Innovations Co (TPE:6934), the current EBITDA Margin % is 16.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HCmed Innovations Co Ltd is engaged in designing, developing, manufacturing and selling drug delivery system. It is focused on inhalation therapy to create integrated drug nebulizer combination products featuring nebulization therapeutic drugs that include small molecule synthetics and large molecule biologics, as either solutions, suspensions, and even difficult-to-deliver high viscosity drugs. Its product includes Pulmogine. Geographically, the company operates in America, Europe, Asian and African regions.
11GF Score
Get the complete analysis for TPE:6934
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6934 has been successfully added to your 
